Please login to the form below

Not currently logged in

Penn Pharma appoints new CEO

Penn Pharma has announced the appointment of a new chief executive officer, Richard Yarwood

Penn Pharma has announced the appointment of a new chief executive officer, Richard Yarwood. He joins the company with more than 33 years experience in the pharmaceutical industry. He will manage the south Wales headquartered business as expands and strengthens its services and international presence.


Richard Yarwood
Richard Yarwood


Yarwood joins the 245-strong team at Penn Pharma to oversee its importation and distribution of clinical trial and commercial material for clients in the UK and internationally. He said: "Penn Pharma is a highly reputable business with a team of experienced and ambitious professionals who have succeeded in building an impressive international presence. 

"I am confident that I will be able to work competently with the team to further strengthen the business's market presence and to ensure that Penn Pharma remains a well-known and well-respected name worldwide."

Yarwood is a pharmacy graduate from Nottingham University. He gained a PhD from Manchester University and an MBA from Warwick University before going onto pursue a successful career in the pharmaceutical industry. He has held senior positions including group president of Sterile Technologies at Catalent Pharma Solutions and president for Europe and Asia Pacific at Catalent.

Penn has also appointed a new operations director, David Cooper, to its senior team. Previously general manager of oral technologies at Zydis, David brings with him extensive experience in global manufacturing, gained from Mylan Pharmaceuticals, formerly Merck Generics. David will be responsible for overseeing operations from Penn Pharma's single-site facility in south Wales. 

Mark Molyneux, chairman at Penn Pharmaceutical Services, said: "These are two key appointments for us at Penn Pharma. Both Richard and David will be valuable additions to our board of directors, and their appointments mark another important step as the company rolls out a £12m expansion programme over the next five years."

30th November 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...